Comparing the current results to its competitors, Aura Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 28.69 %, recorded in the same quarter.
September 12, 2024
Aura Biosciences, a cutting-edge biotechnology firm specializing in the development of novel oncology therapies, recently announced highly promising results from its Phase 2 study of bel-sar as a first-line treatment for early-stage choroidal melanoma. The data reveal an impressive 80% tumor control rate and a 90% preservation of visual acuity, alongside a highly favorable safety profile, marking a significant advancement in ocular oncology.The company revealed these compelling findings at the prestigious Retina Society Annual Meeting. Aura s innovative approach to utilizing bel-sar, through suprachoroidal administration a targeted delivery method that enhances drug efficacy while minimizing adverse effects ...
August 26, 2024
Aura Biosciences has made significant strides in the treatment of early-stage choroidal melanoma, a rare but serious form of eye cancer, by announcing promising Phase 2 end-of-study data regarding their innovative therapeutic agent, bel-sar. This announcement coincides with Aura s upcoming virtual ocular oncology investor event, scheduled for September 12, 2024, at 8:00 AM Eastern Time, where key opinion leaders in the field will provide insights into these development results. Phase 2 Study Overview: Choroidal melanoma affects the pigmented layer of the eye and, if left untreated, can lead to serious complications, including vision loss and metastasis. Traditionally, treatment options have included radiatio...
December 7, 2023
Aura Biosciences Advances First-Line Treatment for Early-Stage Choroidal Melanoma with Bel-sar in Phase 3 Trial Boston-based biotechnology company, Aura Biosciences Inc. (NASDAQ: AURA), has made a significant breakthrough in the field of oncology with the initiation of its Phase 3 CoMpass trial. The trial aims to evaluate the safety and efficacy of Belzupacap Sarotalocan (Bel-sar) for the first-line treatment of early-stage choroidal melanoma in adult patients. Choroidal melanoma, a rare and aggressive form of eye cancer, poses significant challenges in terms of diagnosis and treatment options. With currently available therapies yielding limited success, Aura Biosciences innovative approach using vi...
Compugen Ltd is a technology company that operates on a business model focused on providing innovative solutions to its clients. They utilize their expertise in fields like artificial intelligence, data analytics, and cloud technology to develop software and hardware solutions tailored to meet specific customer requirements. Their business model revolves around offering comprehensive IT services and products aimed at enhancing organizational efficiency and productivity.
Curis Inc's business model revolves around the development and commercialization of innovative cancer therapies. They focus on discovering and advancing drug candidates targeting specific molecular pathways involved in cancer growth and survival. The company collaborates with pharmaceutical partners to conduct clinical trials and seek regulatory approval for their products.
Humacyte Inc is a biotechnology company that focuses on creating bioengineered human tissue constructs for numerous medical applications. Their business model revolves around developing and commercializing their proprietary Humacyl platform, which uses a patient's own cells to create acellular scaffolds that mimic human tissue. These tissue constructs can be used for various purposes such as vascular replacements, functional tissues, and potential regenerative medicine therapies.
Sources:
Aura Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aura Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
